George Kottayil - 10 Nov 2021 Form 3 Insider Report for Acasti Pharma Inc. (GRCE)

Role
COO, US
Signature
/s/ Jason Comerford, Attorney-in-Fact
Issuer symbol
GRCE
Transactions as of
10 Nov 2021
Net transactions value
$0
Form type
3
Filing time
23 Nov 2021, 16:00:44 UTC
Next filing
23 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACST Class A Common Shares 2,222,122 10 Nov 2021 Direct
holding ACST Class A Common Shares 746,064 10 Nov 2021 By Kottayil Grace Pharma LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACST Share Option (Right to Buy) 10 Nov 2021 Class A Common Shares 287,900 $1.63 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 287,900 Class A common shares underlying 287,900 share options granted on November 10, 2021. These share options vest on an even and quarterly basis over 36 months.
F2 Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney